Logo

Vir Biotechnology Collaborates with NIH Vaccine Research Center to Advance the Development of mAbs Against Coronavirus

Share this

Vir Biotechnology Collaborates with NIH Vaccine Research Center to Advance the Development of mAbs Against Coronavirus

Shots:

  • Vir and NIAID will jointly identify and optimize combinations of Ab against coronaviruses- including SARS-CoV-2- SARS- and MERS along with Ab that may show effectiveness across additional types of coronaviruses
  • The collaboration allows Vir to access VRC’s research experience with coronaviruses to accelerate the development of Ab targeting the unmet medical needs of patients
  • Vir has identified several mAbs that bind to SARS-CoV-2 and were isolated from individuals who had survived a SARS infection. The company is evaluating Ab that it may be able to identify from COVID-19 survivors- can be effective as treatment and/or prophylaxis against SARS-CoV-2

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: PRNewswire


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions